All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the MDS Alliance.
The MDS Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy
Introducing
Now you can personalise
your MDS Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for you
Find out moreThe MDS Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the MDS Hub cannot guarantee the accuracy of translated content. The MDS Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
New clinical advances in MDS risk categorization
Bookmark this article
The MDS Hub was pleased to speak to Theo de Witte, Radboudumc, Nijmegen, NL. We asked, What are the new clinical advances in MDS risk categorization?
New clinical advances in MDS risk categorization
In this video, de Witte discusses the current landscape of diagnosis and prognosis for patients with MDS, alongside the current drugs available, including lenalidomide and hypomethylating agents (HMAs). He also highlights how mutations and variant allele frequency (VAF) can affect patient outcome.
More about...
Related articles
Newsletter
Subscribe to get the best content related to MDS delivered to your inbox